Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. The presentation will begin at 9:45 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at http://ir.tevapharm.com. An archived version of the webcast will be available within 24 hours after the

Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference

A jury in Suffolk County State Supreme Court found Teva Pharmaceutical Industries Ltd (NYSE: TEVA) contributed to New York's opioid epidemic. Next, the court will hold another trial to determine how much Teva should pay.

Teva Suffers Loss In New York's Opioid Trial

Alliance Resource Partners

Axon Enterprise

BARK

EverBank Financial

GrowGeneration Corp

Kinross Gold

Kulicke & Soffa Industries

Lumber Liquidators

Lovesac Company

Novavax

Opendoor

Ping Identity Holding Corp

Pinterest

Proto Labs

Pubmatic

Root

StoneCo

Triple-digit returns could be just a click of the buy button away.

22 Stocks That Could Double Your Money in 2022

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up as we round out 2021.

Pot Stocks Closing Out 2021 On a Quiet Note

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -4.57% sank 4.6% in afternoon trading Thursday, reversing an earlier gain of as much as 3.1%, after New York Attorney General Letitia James said a jury found that the drug maker's subsidiary Teva Pharmaceuticals USA and violated rights of New Yorkers, as a contributor to the opioid crisis.

Teva's stock swings to a sharp loss after jury finds its U.S. subsidiary violated rights of New Yorkers

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) strongly disagrees with today's outcome and will prepare for a swift appeal as well as continue to pursue a mistrial. In NY, the plaintiffs presented no evidence of medically unnecessary prescriptions, suspicious or diverted orders, no evidence of oversupply by the defendants – or any indication of what volumes were appropriate – and no causal relationship betw

Teva Statement Following New York Jury Ruling in Opioids Trial

Teva Pharmaceutical Industries Ltd fueled opioid addiction in New York state, a jury found on Thursday, a setback for a company still facing thousands of other opioid-related lawsuits around the United States.

Teva fueled opioid addiction in New York, jury finds

First Majestic Silver

Bank of America

SSR Mining

This mix of growth and value stocks should shine over the long run.

My Top 5 Portfolio Holdings for 2022

Amphastar Pharma

Dr. Reddy's Labs

The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.

3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

This company is facing too many headwinds, and there doesn't seem to be better days ahead.

1 Healthcare Stock to Avoid in 2022

Cannbit-Tikun Olam (TASE:TKUN) will produce various medical cannabis products for Teva Israel, a marketing arm of Teva Pharmaceuticals (NYSE: TEVA). What Happened The Tel Aviv, Israel-based cannabis company confirmed Monday it has signed a collaboration agreement with Teva, under which it will manufacture THC and CBD-rich oils for Teva.

NYSE Traded Teva Pharmaceuticals To Market Cannabis Oils From Cannabit-Tikun Olam In Israel, Palestine, Ukraine

TEL AVIV, Israel, Dec. 27, 2021 /PRNewswire/ -- Teva Israel and Cannbit-Tikun Olam  (TASE: TKUN) signed an exclusive and mutual collaboration agreement, in which Cannbit-Tikun Olam will produce several medical cannabis products, administered as oils rich in THC and CBD, for Teva Israel. This will be done according to Teva's instructions and stringent standards, and the products will be exclusively marketed, and distributed by Teva in Israel and the Palestinian Authority.

First commercial and exclusive agreement signed between 'Teva Israel' and 'Cannbit-Tikun Olam' - for marketing and distribution of medical cannabis oil

The next catalyst for TEVA is likely a jury verdict in the New York trial. I think this will be negative.

Teva: Bracing For Next Catalyst

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of a first-to-market generic version of Narcan®1 (naloxone hydrochloride nasal spray), in the United States. Naloxone hydrochloride nasal spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepi

Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.

Ajovy's sales totaled $108 million in Q3 2021, up 71.4% QoQ and 83.1% Q3 2020. The company's cash flow was $795 million in Q3, up 27.1% QoQ and 57.1% Q3 2021.

Teva: Definitely Undervalued

Amazon

Snowflake

According to the Aggregated Portfolio of Gurus, a Premium feature of GuruFocus, five stocks Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial) and Catherine Wood (Trades, Portfolio)'s ARK Investment Management ( ARKK , Financial) both own are Amazon.com Inc. ( AMZN , Financial), Snowflake Inc. ( SNOW , Financial), StoneCo Ltd. ( STNE , Financial), Teva Pharmaceutical Industries Ltd.

5 Stocks Buffett and Cathie Wood Both Own

Halozyme Therapeutics

Longeveron

Prothena

Cassava Sciences Inc

Sesen Bio Inc.

Takeda Pharmaceutical

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

bluebird bio

There's an entire galaxy full of better places to invest your money.

2 Popular Healthcare Stocks I'd Avoid at All Costs

Bristol-Myers

Visa

Riding the Oracle of Omaha's coattails is often a moneymaking proposition.

5 Warren Buffett Stocks Are Screaming Buys in December

TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of an authorized generic of Epiduo®1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States. Adapalene and benzoyl peroxide gel 0.3%/2.5% is a topical prescription medicine used to treat acne vulgaris. “The launch of our first-to-market authorized generic version of Epiduo® Forte Gel in the U.S. prov

Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.

Bargains abound for growth and value investors.

3 Top Stocks That'll Make You Richer in December (and Beyond)

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) and that it is increasing the combined aggregate purchase price (exclusive of accrued and unpaid interest) (the “Total Maximum Amount”) from $3,500,000,000 to $4,000,000,000 for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 1.250% Senio

Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement

Mastercard

Riding the Oracle of Omaha's coattails has been a moneymaking move for decades.

4 No-Brainer Buffett Stocks to Buy With $500 in November

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced ambitious commitments to address two of today's greatest global crises—access to medicines and climate change—tied to its recently issued $5 billion sustainability-linked bond. The bond is linked to three targets, including a 25% reduction in Scope 1 and 2 greenhouse gas (GHG) emissions and a 150% increase in access to essential medicines for patients in low- and middle-income countries (LMICs

Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine Targets

Teva Pharmaceutical Industries Ltd. TEVA, +9.53% said Wednesday it is planning to execute a $5 billion sustainability-linked bond that will be tied to climate and access to medicine targets.

Teva Pharmaceuticals plans $5 billion sustainability-linked bond tied to climate and access to medicine targets

News for Teva Pharmaceutical Stock (TEVA)